| Objective: Gastric cancer is a common malignant tumor, which is the second cause of cancer-related deaths in global cancer mortality. The majority of patients will relapse after radically surgery, and 5-year survival after surgery remains poor. The role of adjuvant therapy in gastric cancer has been controversial and there is no standard regimens. The purpose of this study is to evaluate the efficacy and toxicity of combination regimens with oxaliplatin plus fluorouracil and leucovorin (oxaliplatin-based regimen) or paclitaxel plus fluorouracil and leucovorin (paclitaxel-based regimen) as post-operative adjuvant chemotherapy in advanced gastric cancer.Methods: Fifty-one patients with radical gastrectomy were enrolled. Thirty-seven patients were enrolled in oxaliplatin-based regimen, while the other 14 patients were enrolled in paclitaxel-based regimen.Results: Fourty-seven gastric cancer patients from two groups had intact follow-up data. One-year disease free survival rate (1-yr DFS) of oxaliplatin-based regimen and paclitaxel-based regimen are 72.7% and 64.3% respectively (p=0.818). One-year overall survival rate (1-yr OS) of two regimens are 87.9% and 78.6% respectively (p=0.410). Two-year disease free survival rate (2-yr DFS) of two regimens are 72.7% and 57.1% respectively (p=0.480). Two-year overall survival rate (2-yr OS) of two regimens are 78.8% and 57.1% respectively (p=0.246). Disease free survival rate and overall survival rate in oxaliplatin-based regimen is superior to paclitaxel-based regimen, but no statistic difference was observed. No severe toxicity was observed in both groups. The frequent grade III-IV toxicity such as neutropenia, nausea and neurotoxicity were more often in the oxaliplatin-based regimen than those in the paclitaxel-based regimen.Conclusions: Oxaliplatin plus fluorouracil and leucovorin or paclitaxel plus fluorouracil and leucovorin as post-operative adjuvant chemotherapy in radically resected gastric cancer are effective and well-tolerable. |
PDF Full Text Request